Niagen Bioscience Inc (NASDAQ:NAGE) price on Friday, April 11, rose 4.59% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.93.
A look at the stock’s price movement, the close in the last trading session was $5.67, moving within a range at $5.59 and $5.94. The beta value (5-Year monthly) was 2.184 while the PE ratio in trailing twelve months stood at 56.32. Turning to its 52-week performance, $9.18 and $2.31 were the 52-week high and 52-week low respectively. Overall, NAGE moved -23.19% over the past month.
Niagen Bioscience Inc’s market cap currently stands at around $461.07 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-03.
Analysts have a consensus estimate of 27.07M for the company’s revenue for the quarter, with a low and high estimate of 26.9M and 27.2M respectively. The average forecast suggests up to a 22.22% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 118.5M, representing a 18.98% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NAGE is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
The technical evaluation for the stock shows the PEG ratio is 1.48, with NAGE’s current price about -14.09% and -8.59% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.25, while 7-day volatility ratio is 11.01% and 6.79% in the 30-day chart. Further, Niagen Bioscience Inc (NAGE) has a beta value of 2.01, and an average true range (ATR) of 0.50.
If we refocus on Niagen Bioscience Inc (NASDAQ:NAGE), historical trading data shows that trading volumes averaged 0.79 over the past 10 days and 866.94K over the past 3 months. The company’s latest data on shares outstanding shows there are 77.33 million shares.
The 36.68% of Niagen Bioscience Inc’s shares are in the hands of company insiders while institutional holders own 29.24% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.11 million on 2025-02-28, giving us a short ratio of 5.91. The data shows that as of 2025-02-28 short interest in Niagen Bioscience Inc (NAGE) stood at 418.0 of shares outstanding, with shares short falling to 2.11 million registered in 2025-01-31. Current price change has pushed the stock 11.78% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NAGE stock continues to rise going into the next quarter.
